BioMarin Pharmaceutical (BMRN) Balance Sheet

Current and historical balance sheet items (assets, liabilities and equity) for BioMarin Pharmaceutical (BMRN) over the last 10 years.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.399B $1.117B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.